CRSP241213P39000
- 0.04
- 0.000.00%
CRISPR Therapeutics Newsroom
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
CRISPR Therapeutics Analyst Ratings
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $95
A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $94
Oppenheimer Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Exact Sciences (EXAS) and Crispr Therapeutics AG (CRSP)
Crispr Therapeutics AG: Hold Rating Amid Mixed Financial Performance and Clinical Developments
Crispr Therapeutics Price Target Maintained With a $84.00/Share by Needham
CRISPR Therapeutics Analyst Ratings
Barclays Remains a Hold on Crispr Therapeutics AG (CRSP)
Mizuho Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Crispr Therapeutics AG (CRSP) Gets a Buy From Mizuho Securities